Terran Biosciences is a New York-based drug discovery platform company developing transformative therapeutics for neurological and psychiatric diseases. Founded by CEO Samuel Clark, the company holds over 200 patent applications covering novel formulations of psychedelic compounds including LSD, DMT, psilocybin, and MDMA, and operates clinical programs in schizophrenia and depression. Its AI-enabled neuromelanin MRI software platform NM-101 has received FDA clearance.
Drug Pipeline
3TerXT
Long-acting combination of novel prodrugs of xanomeline and trospium for schizophrenia; designed for 505(b)(2) regulatory pathway.
Idazoxan XR
Once-daily oral alpha-2 adrenergic receptor antagonist with novel mechanism; currently in clinical study for schizophrenia.
Psychedelic + 5-HT2A Antagonist Combination
Fixed-dose combination of a psychedelic with a selective 5-HT2A receptor antagonist designed to remove hallucinogenic effects while preserving antidepressant efficacy.
Quick Facts
- Type
- Private Biotech
- Founded
- 2017
- Lead Stage
- Phase II
- Website
- Visit